ANRO
Alto Neuroscience, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Alto Neuroscience has 10 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIn October 2021, we entered into an asset purchase agreement, or the Teva Agreement, with Teva Pharmaceutical Industries, Ltd. and its affiliate Cephalon, Inc., or, together Teva, pursuant to which we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds, and we assumed all post-acquisition liabilities related thereto.
SentenceIn December 2019, we entered into an exclusive license agreement with equity, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, which was subsequently amended in May 2020 and December 2023.
ANRO 10-Kaccession 0001999480-26-000002
SentenceIn May 2025, we entered into an asset purchase agreement, or the Chase Agreement, with Chase Therapeutics Corporation, or Chase, pursuant to which we acquired all patent, know-how and other rights to ALTO-207, ALTO-208, and certain related asset, or the Acquired Chase Compounds.
ANRO 10-Kaccession 0001999480-26-000002
SentenceIn connection with the transactions effected by the Palisade Agreement, Palisade also transferred and assigned to us all right, title, and interest in, to, and under an exclusive license agreement, or the Dow Agreement, between Dow Agrosciences LLC, or Dow, and Palisade (f/k/a Neuralstem, Inc.), dated as of December 1, 2016, as a result of which we obtained an exclusive, sublicensable license under certain patent rights of Dow to make, have made, use, and have used, certain compounds covered by such patent rights and to make, have made, offer for sale, sell, import, and have imported, products using such compounds, including Palisade Acquired Products, for the development, synthesis, and commercialization of such products as prescription human pharmaceutical in the United States.
ANRO 10-Kaccession 0001999480-26-000002
SentenceFor example, we depend on licenses from Sanofi and MedRx for certain intellectual property relating to the development and commercialization of ALTO-101.
ANRO 10-Kaccession 0001999480-26-000002
SentenceMerck and its affiliates retained a co-exclusive, worldwide right under Merck's patent rights and know-how sublicensed to us by Cerecor to research, make, have made, use and import ALTO-202 and Cerecor Licensed Products solely for non-human, non-commercial purposes, and we received a non-exclusive worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights covering improvements made by Merck through its exercise of such retained right.
ANRO 10-Kaccession 0001999480-26-000002
SentenceIn October 2021, we entered into an asset transfer agreement, or the Palisade Agreement, with Palisade Bio, Inc., or Palisade, pursuant to which we acquired all patent, know-how and other rights to ALTO-100.
ANRO 10-Kaccession 0001999480-26-000002
SentenceThe Convertible Grant Agreement provides for an unsecured convertible loan, or the Convertible Loan, from Wellcome of up to approximately $11.7 million, payable in six tranches.
ANRO 10-Kaccession 0001999480-26-000002
SentenceThe Convertible Grant Agreement provides for the Convertible Loan from Wellcome of up to approximately $11.7 million, payable in six tranches.
ANRO 10-Kaccession 0001999480-26-000002
—
Alto Neuroscience, Inc.
22.40
−1.07 · −4.56%
post 22.40 −0.01%
Linked news
Expected move
Inputsstraddle ±16.7%
spot 22.60exp Nov 20ATM strike 22.5ATM straddle 4.45IV 103%